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SUMMARY – Recent research has revealed the genetic etiology of a number of heart diseases 
that cause sudden cardiac death. Lethal channelopathies are of great importance among the geneti-
cally determined heart diseases. Th eir basic characteristics are unpredictable and deadly nature, auto-
somal dominant inheritance with variable expressivity and incomplete penetrance in structurally nor-
mal heart, and absence of morphological and histological clues that a standard autopsy can identify. 
Minimum screening of the relatives of sudden cardiac death victims involves taking medical history, 
physical examination, electrocardiography, echocardiography, and exercise testing. Total positivity of 
classic genetic tests is only 15%-25%. Even the next generation sequencing technology does not pro-
vide a positive result of genetic testing in more than 35% of cases. Th erefore, it is necessary to identify 
a larger number of genes the presence of which can lead to sudden cardiac death, to reduce the number 
of false positive results, and point to the importance of conducting genetic testing of young victims of 
sudden cardiac death. Until then, it is enough to preserve 5 g of fresh heart tissue of sudden cardiac 
death victims at a temperature of -80 °C. Th e material can be analyzed years later without losing its 
actuality because it contains information important for the next generation of the sudden cardiac 
death victim relatives.
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Introduction
When an elderly person has a cardiovascular dis-
ease, he/she is aware of the risk that the disease brings, 
including death. Even 10%-32% of adults die sudden-
ly1. When a newborn, infant, toddler, adolescent, or 
young adult dies from heart disease, then it is a tragedy 
for the victim and for the parents who fi nd it diffi  cult 
to accept the fact that their children are mortal. Recent 
research in the fi eld of genetics has revealed the ge-
netic etiology of a number of heart diseases that cause 
sudden cardiac death, which pose a serious dilemma 
because heritability of the underlying disease puts the 
surviving relatives at risk of sudden death and confers 
urgency of its timely identifi cation in order to design 
preventive treatment2,3. Genetically determined heart 
diseases are responsible for more than 50% of sudden 
cardiac deaths in children4.
Defi nition of Terms and Scope of the Problem
In order to get better view and understanding of 
the problem of sudden death, it is necessary to follow 
the defi nitions of some terms that are in close connec-
tion with it. Sudden death (SD) is defi ned as an unex-
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pected natural death in apparently healthy individuals 
that takes place during the fi rst hour after the onset of 
symptoms5. Sudden cardiac death (SCD) is defi ned as 
a witnessed, natural unexpected death from cardiac 
causes occurring within one hour after the onset of 
symptoms in a previously healthy person or an unwit-
nessed natural unexpected death of a person observed 
to be well within 24 h of being found dead6. Sudden 
unexpected death (SUD) is a non-traumatic death 
that occurs instantaneously or within 24 hours of the 
onset of acute symptoms or signs1. Sudden infant 
death syndrome (SIDS) is a category of children 
younger than 1 year, including 70% to 80% of SUD 
victims with no identifi able cause found on postmor-
tem investigation7.
By analyzing the relatively small number of pub-
lished studies that address the incidence of SCD of 
infants, children, adolescents and young adults, as well 
as according to many years of our experience as pediat-
ric cardiologists, we can conclude that SCD is rela-
tively uncommon, with an incidence of 1.3 to 8.5 per 
100 000 patient-years4. A Danish study showed the 
incidence of SCD to be 2.8 per 100 000 person-years 
in a population aged 1-35 years8. Croatian physicians 
published the results on SCD in sport active persons 
aged up to 35 years with the total incidence of 0.06/
100 000 per year9. It is obvious that the number of po-
tential victims is not large, but the fact that the back-
ground of many of these deaths can be genetically con-
ditioned by arrhythmogenic syndromes and that sev-
eral other asymptomatic family members can be af-
fected by the same disease, requires that SUD in 
patients younger than 35 years be carefully studied.
Defi ning the Cause of Sudden Death
Th e age of the victim largely indicates the cause of 
death. Ischemic heart disease is the leading cause of 
death in people older than 35 years, while the most 
common cause of death of people younger than 35 
years is cardiomyopathy, followed by ischemic heart 
disease, valvular disease, and diseases of the conduc-
tion system of the heart10-14.
Lethal channelopathies are of great importance 
among the genetically determined heart diseases. Th eir 
basic characteristics are unpredictable and deadly na-
ture, autosomal dominant inheritance with variable 
expressivity, incomplete penetrance in structurally nor-
mal heart, and absence of morphological and histo-
logical clues that a standard autopsy can identify15,16. 
Th e pathophysiological mechanism that leads to a fatal 
outcome is electric dysfunction caused by genetic de-
fects of the genes encoding the subunits of cardiac ion 
channels or regulatory proteins in ion channels of car-
diac muscle cells. Th e most important among them are 
the long QT syndrome (LQTS), shortened QT inter-
val syndrome (SQTS), catecholaminergic polymor-
phic ventricular tachycardia (CPVT), and Brugada 
syndrome (BrS).
Symptoms and Th eir Importance
Numerous symptom diversities are most evident in 
the case of Brugada syndrome (BrS). Th ere is the 
greatest possible range of symptoms depending on 
penetrance and expressivity, from completely asymp-
tomatic carriers with fully normal length of life and 
quality of life to a sudden death in the fi rst year of 
life17. Typical for this syndrome is considered to be a 
situation where the victim of SD is a man aged about 
40 who died in sleep18. Th e largest series of studied 
results of molecular autopsy showed that the largest 
number of SUD (33%) occurred in dream or during 
exercise19.
Th e existence of asymptomatic carriers of heredi-
tary arrhythmogenic syndromes is of particular impor-
tance because medical history hides plenty of subtle, 
nonspecifi c symptoms expressed by a number of SD 
victims. Nonspecifi c symptoms, such as syncope, were 
present in a Swedish study of SCD victims from 15 to 
35 years of age, which showed that 46% of SCD vic-
tims sought medical assistance due to the presence of 
symptoms before the tragic event20. Besides the fact 
that vaso-depressor syncope is not a predictive factor 
for SD, it is possible to extract syncope that requires a 
more extensive evaluation looking for possible cardiac 
etiology21,22. Th e existence of warning signs was identi-
fi ed in half of the victims with channelopathies in per-
sonal or family history, citing as an example that 30% 
of cases of SCD as a consequence of CPVT, family 
history contains information on one or more prema-
ture deaths by the age of 4019,23,24.
Cardiac arrest may be the fi rst clinical manifesta-
tion in apparently healthy people, while the cardiac ar-
rest interrupted by resuscitation measures occurs in 
5%-10% of patients with LQTS25. Death is the fi rst 
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symptom of the disease in 30% of cases with CPVT24. 
Pronounced penetrance of the pathogenic CPVT vari-
ant RyR2 has a mortality rate of 30%-50% by 35 years 
of life, resulting in a small number of asymptomatic 
carriers26,27.
In addition to the corpus of common symptoms, 
each of hereditary arrhythmogenic syndromes has its 
own distinctive clinical characteristics. CPVT is typi-
cally manifested in eff ort syncope, syncope during 
emotional stress, or sudden death as a result of poly-
morphic ventricular tachycardia during childhood, 
adolescence or young adulthood. Heart rhythm disor-
der in LQTS can be caused by excessive physical activ-
ity, swimming, emotional stress, sound stimuli (e.g., 
alarm clock), etc.
Recommended Diagnostics 
in SCD Victims and Th eir Relatives
Of particular importance is the fact that it is diffi  -
cult to determine the cause of death in infants and 
young adults undergoing autopsy with negative result. 
In these cases, it is deemed that death occurred due to 
hereditary arrhythmogenic syndromes in a structurally 
normal heart28. Under a structurally normal heart is 
deemed the heart without minimum macroscopic and 
microscopic deviations, including mild fatty infi ltra-
tion of the right ventricle and slight myxomatous mi-
tral valve19. It was concluded that arrhythmia caused 
death of 35% of autopsy-negative SD victims during 
the 25 years of studying the causes of SD in one US 
military base10.
When standard autopsy cannot determine the 
cause of death, other diagnostic possibilities are ge-
netic testing of members of the victim’s family and 
molecular autopsy. Testing of family members has a 
diagnostic, prognostic and therapeutic implications for 
relatives of those victims whose genetic tests are nega-
tive, and for those relatives of victims without clinical 
signs of disease whose genetic tests are positive29. Mo-
lecular autopsy is a process where DNA is extracted 
from the blood after death and then the selected genes 
responsible for major primary arrhythmogenic diseas-
es are analyzed30. Diagnostic capacities of molecular 
autopsy can signifi cantly infl uence prevention of SCD 
in the general population. Th e formation of multidisci-
plinary teams consisting of a pathologist, geneticist 
and cardiologist allows for more effi  cient transfer of 
information among health professionals in relation to 
the victim’s family, thus increasing the coverage of 
families that participate in genetic counseling and car-
diac treatment in order to identify asymptomatic car-
riers of hereditary arrhythmogenic syndromes31.
Geneticists are expected to provide genetic coun-
seling of family members of SCD victims with de-
tailed information on the risks, benefi ts and options 
available for clinical genetic testing. Clinical cardiac 
evaluation of SCD victim’s relatives considers collect-
ing data from personal and family medical history and 
clinical cardiologic examination, which is invaluable 
for diagnosis. Th e introduction of a minimum SCD 
screening for all relatives of the fi rst order autopsy-
negative victim is proposed in some studies, including 
taking detailed personal and family history, physical 
examination, 12-channel electrocardiography (ECG), 
stress test, and echocardiography32. Th e same source 
suggests that an alternative or even simultaneous mo-
lecular autopsy for the major genes for LQTS, CPVT 
and BrS be done as part of standard procedure in the 
evaluation of autopsy-negative SUD victims younger 
than 40 years33. Other sources pay special attention to 
detailed history data collected, which indicate the cir-
cumstances in which the death occurred and the age at 
which the victim died3. It is also recommended that 
12-channel ECG recording at rest be made in the sur-
viving relatives, as well as exercise testing and 2D 
echocardiography. Flecainide test is recommended 
when there is suspicion of BrS. In the cited study, mo-
lecular genetic analysis was conducted on surviving 
relatives, but not molecular autopsy. Candidates for 
genetic analysis are selected on the basis of the results 
of clinical trials3.
Some studies suggest the use of a combined ap-
proach as a rational diagnostic variant. It implies that 
the SCD victim’s family are informed on the suspected 
genetic background of SCD and the need for cardiac 
evaluation. At the same time, molecular analysis should 
be conducted in the SCD victim, as these results are 
better interpreted integrally with clinical assessment of 
the family members of SCD victims. In case of posi-
tive molecular autopsy, DNA screening can be extend-
ed to family members to identify carriers of the same 
mutation. Th e aim of the implementation of molecular 
autopsy is to increase the reliability of diagnosis and 
facilitate cascade screening of family members with a 
focus towards targeted testing34,35
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Danish Statens Serum Institute and Department 
of Cardiovascular Diseases in Rijeka followed the in-
tegrated standard clinical approach and genetic analy-
sis in all patients with clinical diagnosis of hereditary 
arrhythmogenic syndromes and their relatives. Th ey 
proved that combined approach allowed better identi-
fi cation of patients at an increased risk of SCD36.
Plenty of good practice found in the literature still 
does not give a precise answer to the questions: which 
relatives should be treated cardiologically and which 
scope of other diagnostics to apply? In the search for 
answers to these questions, we should bear in mind the 
fact that over 95% of hereditary arrhythmogenic syn-
dromes in the general population are inherited in the 
autosomal-dominant pattern, so that fi rst-degree rela-
tives have a one in two (50%) chance of inheriting the 
gene mutation, and clinical evaluation of the fi rst-or-
der relatives is of utmost importance37,38. Results of 
clinical trials conducted in 2005 in young fi rst-order 
relatives of SCD victims showed that 28% of them had 
heart channelopathies that could be identifi ed38. More 
convincing are results of a study from 2008, which 
showed that the diagnosis of hereditary arrhythmo-
genic syndromes was detected in 53% of fi rst-order 
relatives of SCD victims after conducting a detailed 
cardiology examination39.
Clinical screening of SCD victim’s family members 
is most successful if the existence of genetic mutations 
confi rmed by molecular autopsy is detected in the 
SCD victim31. Molecular genetic analysis can be of 
great help to confi rm the diagnosis in cases where 
there is not a striking enough phenotype40. However, 
the reliability of the clinical diagnosis is not in ques-
tion when the result of the molecular genetic analysis 
is negative41
In order to assess the role and how to use genetic 
testing to identify hereditary arrhythmogenic syn-
dromes, the European Heart Rhythm Association 
gathered a multidisciplinary team of experts who pre-
pared the guidelines for the conditions in which ge-
netic testing should be conducted30. Th e level of con-
fl ict in relation to the application of genetic testing is 
evident from the information that the experts them-
selves (who participated in drafting the guide) were 
not united and achieved consensus on all recommen-
dations in 84% of cases, whereas on most they were 
consistent in 94% of cases30.
Although the results of some studies have shown a 
particularly high level of positive molecular tests in 
SCD victims and their families, the real situation is far 
from satisfactory. Th e current generation of the LQTS 
mutation test gives positive result in 75% of the test 
and in less than 20% of SQTS cases30. Total positivity 
of genetic testing is not more than 15%-25%42. How-
ever, recent development of the next generation se-
quencing technologies (NGS) allows the analysis of a 
greater number of genes with reduced time and cost. 
Th e NGS technology rises the percentage of the po-
tential pathogenic variants associated with arrhythmo-
genic syndromes leading to SCD to up to 35%43,44.
It is the obligation of medical professionals to pro-
vide the victim’s family with answers (to the possible 
extent) to the questions of what led to death of their 
family member and whether any of the surviving rela-
tives is a potential victim. Th e task of multidisciplinary 
teams is to minimize the risk of misinterpretation of 
autopsy fi ndings, results of genetic tests and borderline 
results of cardiac tests44.
Genetic Testing as Part 
of the Standard Diagnostic Procedure
Identifi cation of the people at risk of SCD is im-
portant because of the possibility of the application of 
preventive measures in the surviving family members 
of SCD victims. Th ese are mostly channelopathies 
with structurally normal heart, which can be treated 
successfully, life can be extended, and better quality 
of life can be provided by using reliable prophylaxis 
(beta-blockers, sodium channel blockers in LQTS, 
implantable cardioverter defi brillator), which signifi -
cantly lowers the risk of SCD45-48.
Despite the fact that DNA analysis of SCD vic-
tims opens new diagnostic features, it is still not part of 
the routine testing in any country of the world. In or-
der to make genetic testing for hereditary arrhythmo-
genic syndromes part of the standard test procedures, 
it is necessary fi rstly to identify a much larger number 
of pathologic genes the presence of which can lead to 
SCD. For now, only one gene unique to BrS is known 
and mutation can be identifi ed in 30% of patients49. In 
addition, it is necessary to shorten the length of ge-
netic testing to improve their practical value49. Also, it 
is necessary to reduce the number of ‘unsafe’ genetic 
screening which originates from identifi cation of ge-
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netic variants that cannot be declared as pathogenic 
with great certainty. Th e term “variant of uncertain sig-
nifi cance” refers to false-positive results of genetic 
tests, their percentage varying depending on the type 
of disease. For example, CPVT has a relatively low 
level of false-positive results of genetic testing, while 
there is an extremely high level of false-positive results 
of genetic testing for arrhythmogenic right ventricular 
cardiomyopathy, which is explained by the identifi ca-
tion of rare, non-pathogenic mutations30. It is impor-
tant to note that there is currently a struggle for su-
premacy among genetic testing laboratories over rele-
vant intellectual property for heart rhythm disorder 
testing in order, they say, to produce more comprehen-
sive and accurate test results50.
Financial aspect of the implementation of genetic 
testing is one of the challenges for their full integra-
tion into the standard package of tests. First, the con-
cept and the contents of molecular autopsy is not fully 
defi ned, and it is not possible to determine the exact 
price of ‘positive genotype’41. It is diffi  cult to justify the 
high cost of genetic testing since it is not directly in-
tended to provide medical services and it is not used 
for treatment, as medical service is only evaluated in 
lay terms. Out of medical profession, it is not possible 
to justify the use of molecular autopsy in every SIDS 
since the test conducted on a sample of 200 SIDS vic-
tims showed mutations in the coding of ion channels 
typical of LQTS in 8.3% of cases51. Some studies indi-
cate that testing of the SIDS victims is positive for 
LQTS, CPVT and BrS together in only 10%-15% of 
cases30. However, some health insurance systems have 
recognized the importance of NGS-based genetic 
tests to be eligible for coverage of hereditary disease. 
Reimbursement catalogue of the Germany statutory 
health insurance system that took eff ect July 1, 2016, 
classifi es NGS genetic diagnostic tests for coverage re-
quiring pre-authorization of tests analyzing more than 
25 kilobases of DNA52.
Th e advantage of molecular autopsy over clinical 
evaluation of family members is not convincingly 
proven, and it is still easier to accept the necessity to 
make cardiologic testing in a large number of family 
members of SCD victims. Even the fact that 75% of 
patients with LQTS phenotype are carriers of specifi c 
genetic mutations with 45% diagnostic reliability in 
the case of negative family history and uncertain or 
borderline clinical signs is not persuasive yet53. While 
waiting for clarifi cation of the basic dilemmas of the 
contents of diagnostic procedures and order of their 
application, as well as the completion of pathologic 
genes and reduction in the price of genetic tests, the 
option is available of simple sampling 5 g of fresh heart 
tissue or 10 mL of blood in EDTA SCD victim, and 
preserve it at a temperature of -80 ˚C54. Th e human 
material thus obtained can be analyzed years after 
sampling without losing its relevance because it con-
tains information of importance to the next generation 
of SCD victim’s relatives.
Genetic testing in identifi cation of the people at 
risk of SCD is important but still with many open 
questions. Th is diagnostic tool gives the possibility of 
applying preventive measures for surviving of SCD 
victim family members.
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Sažetak
GENETIČKI ASPEKTI IZNENADNE SMRTI KOD PRIROĐENIH ARITMOGENIH SINDROMA
V. Miranović i S. Crnogorac
Novija istraživanja na polju genetike su otkrila nasljednu etiologiju jednog broja srčanih bolesti koje izazivaju iznenadnu 
srčanu smrt. Smrtonosne kanalopatije su od velike važnosti među genetski uvjetovanim bolestima srca. Njihova temeljna 
obilježja su nepredvidiva i smrtonosna narav, autosomno dominantno nasljeđe s varijabilnom ekspresivnosti i nepotpunom 
penetrantnosti u strukturalno normalnom srcu u odsutnosti morfoloških i histoloških naznaka koje se mogu identifi cirati 
standardnom obdukcijom. Minimalni odabir srodnika žrtve iznenadne srčane smrti obuhvaća uzimanje anamnestičkih 
 podataka, fi zikalni pregled, kardiološki pregled, elektrokardiografi ju, ehokardiografi ju, test opterećenja. Ukupna pozitivnost 
klasičnih genetskih testova za otkrivanje urođenih bolesti srca je od 15% do 25%. Ni nova generacija tehnologije sekvencira-
nja ne nudi pozitivan rezultat genetskog testiranja u više od 35% slučajeva, ni uz to što postupak testiranja traje kraće i jefti-
niji je. Zato je potrebno identifi cirati veći broj gena prisustvo kojih može dovesti do iznenadne srčane smrti, smanjiti broj 
lažno pozitivnih rezultata genetskog testiranja, sigurnije ukazati na značenje provođenja genetskog testiranja mladih žrtava 
iznenadne srčane smrti, kako bi genetsko testiranje postalo dio standardnog dijagnostičkog postupka. Do tada je dovoljno 
uzeti i sačuvati 5 g svježeg srčanog tkiva žrtve iznenadne srčane smrti na temperaturi od -80 ˚C. Uzeti materijal može se 
analizirati i mnogo godina nakon uzimanja ne gubeći na aktualnosti, jer u sebi sadrži informaciju od važnosti za sljedeće 
generacije srodnika žrtve iznenadne srčane smrti.
Ključne riječi: Srčane bolesti; Smrt, iznenadna, srčana; Autopsija; Ehokardiografi ja; Genetsko testiranje; Visoki protok (pro-
pusnost) nukleotida, sinkroniziranje
